Ripamonti

84.6k citations
1.6k papers ·

Impact in

Papers in

    • Cancer-related Molecular Pathways 51
    • HER2/EGFR in Cancer Research 47
    • Cancer Risks and Factors 44
    • Breast Cancer Treatment Studies 152

Ripamonti

1.4k papers receiving 74.6k citations

Peers

Ripamonti
Comparison fields: 5 of 227
  • Oncology 21.9k
  • Cancer Research 11.7k
  • Cell Biology 9.7k
  • Modeling and Simulation 2.3k
  • Molecular Biology 28.4k
Replace IFOM with:
IFOM Italy
Institut pour l'avancée des biosciences France
VIB-KU Leuven Center for Cancer Biology Belgium
Institute of Oncology Research Switzerland
La Ligue Contre le Cancer France
Roche Pharma AG (Germany) Germany
VIB-UGent Center for Inflammation Research Belgium
Swiss Group For Clinical Cancer Research Switzerland
Biologie cellulaire et Cancer France
Centre Georges François Leclerc France
Ripamonti relative to IFOM Italy IFOM's profile →
Citations per field
00.5×2×4×5.1×
IFOM · 1×
Citations per year

Countries citing scholars working at Ripamonti

Since Specialization
Citations

This map shows the geographic impact of research produced by authors working at Ripamonti. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Ripamonti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ripamonti more than expected).

Fields of papers published by authors at Ripamonti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers affiliated with Ripamonti at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Ripamonti at the time of their publication.

About Ripamonti

In recent decades, authors affiliated with Ripamonti have published 1.6k papers, which have received a total of 84.6k indexed citations . Scholars at this organization have produced 441 papers in Oncology, 221 papers in Cancer Research, 46 papers in Modeling and Simulation, 36 papers in Otorhinolaryngology and 175 papers in Radiology, Nuclear Medicine and Imaging on the topics of Breast Cancer Treatment Studies (152 papers), Breast Lesions and Carcinomas (56 papers), Breast Implant and Reconstruction (51 papers), Cancer-related Molecular Pathways (51 papers), HER2/EGFR in Cancer Research (47 papers), Cancer Risks and Factors (44 papers), Radiomics and Machine Learning in Medical Imaging (43 papers) and Advanced Radiotherapy Techniques (43 papers). Their work is cited by papers focused on Oncology (21.9k citations), Cancer Research (11.7k citations), Cell Biology (9.7k citations), Modeling and Simulation (2.3k citations) and Molecular Biology (28.4k citations). Authors at Ripamonti collaborate with scholars in Italy, United States and Germany and have published in prestigious journals including European Journal of Cancer, The Breast, Breast Cancer Research and Treatment, Cancers and European Journal of Nuclear Medicine and Molecular Imaging. Some of Ripamonti's most productive authors include Alberto d’Onofrio, Peter A. Boyle, Pier Paolo Di Fiore, Patrick Maisonneuve, Edward D. Salmon, Giuseppe Viale, Pier Giuseppe Pelicci, Umberto Veronesi, Sara Gandini and Giuseppe Curigliano.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore institutions with similar magnitude of impact